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The presence of a strongly immunosuppressive 
tumor microenvironment and metastasis at time 
of diagnosis represent two fundamental obsta-
cles to the treatment of cancer. Tumor-associated 
macrophages are frequently observed to be im-
munosuppressive and functionally polarized to 
promote tumor growth and metastasis (Lin et al., 
2001; Serafini et al., 2006a; Sica et al., 2008; 
Qian et al., 2009). Indeed, these studies have 
highlighted a direct correlation between extrav-
asation and metastatic potential of tumors with 
the infiltration of tumors by macrophages (Lin 
et al., 2001; Qian et al., 2009). Although the com-
plex interactions between macrophages and   
tumor cells are incompletely defined, it has be-
come increasingly evident that the production 
of proteases, growth factors, and cytokines by 
macrophages may enhance the efficiency of the 
metastatic process. However, macrophages ex-
hibit a large degree of plasticity in that their   
cellular responses can be profoundly influenced 
by the cytokine and cellular environment. In this 
regard, IL-12 has emerged as a promising thera-
peutic agent in that it functionally alters tumor-
associated macrophages toward an anti-tumor 
anti-metastatic  profile  (Watkins  et  al.,  2007). 
Previously, we reported that IL-12–based com-
bination cytokine immunotherapies, namely   
IL-2/IL-12 and IL-2/anti-CD40, can effectively 
alter the balance of the tumor microenvironment 
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Using an orthotopic model of renal cell carcinoma, we showed previously that IL-2/ 
anti-CD40 immunotherapy resulted in synergistic anti-tumor responses, whereas IL-2 or  
-CD40 alone mediated partial transient anti-tumor effects. We now show that treatment of 
tumor-bearing mice with IL-2/-CD40, but not IL-2 or -CD40, induced significant nitric 
oxide synthase (NOS) 2 expression in tumor-associated macrophages. In control-treated mice 
(low NO), NOS2 inhibition reduced tumor burden. However, during immunotherapy (high NO), 
NOS2 inhibition or macrophage depletion reversed the ability of IL-2/-CD40 treatment to 
reduce lung metastases but had no effect on primary tumor burden. Furthermore, IL-2/ 
-CD40 induced the IFN-– and NO-dependent decrease in matrix metalloproteinase (MMP) 
expression and activity, concomitant with increases in tissue inhibitor of metalloproteinase 
(TIMP) 1 and E-cadherin expression within tumors. Finally, treatment of tumor-bearing mice 
with the NO donor JS-K significantly reduced metastases. These data differentiate the mech-
anism for primary anti-tumor effects of IL-2/-CD40 immunotherapy, which are independent 
of NO, from the NO-dependent inhibition of metastases. Furthermore, reduced MMP9 activ-
ity implicates M1-polarized macrophages within the tumor microenvironment as critical 
components of therapeutic response. Our data demonstrate the mechanistic basis for IL-2/ 
-CD40–mediated control of metastases and suggest that the context-dependent application 
of NO donors may hold promise for prevention of metastatic disease.
This article is distributed under the terms of an Attribution–Noncommercial–Share 
Alike–No Mirror Sites license for the first six months after the publication date 
(see http://www.rupress.org/terms). After six months it is available under a Cre-
ative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported 
license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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reduced arginase expression concomitant with the produc-
tion of Th1 cytokines (e.g., IFN-, MIG, IP-10, and RANTES) 
by other inflammatory leukocytes that are associated with   
favorable prognosis (Wigginton et al., 1996b; Weiss et al., 
2009). In this study, we confirm and extend this hypothe-
sis by demonstrating that the anti-metastatic potential of   
IL-2/-CD40 immunotherapy is critically dependent on 
macrophage-dependent NO expression within the tumor 
microenvironment. Furthermore, we demonstrate, for the 
first time, a clear example whereby a successful immunother-
apeutic regimen against a primary tumor is NO independent, 
whereas concomitant control of metastatic spread to lungs is 
NO dependent. Importantly, IL-2/-CD40 induced the re-
duction  in  MMP  expression  and  activity  and  increased   
E-cadherin expression. Thus, IL-2/-CD40 achieves a re-
duction in the ratio of MMP/E-cadherin expression within 
the tumor microenvironment that has been associated with 
favorable  prognosis  in  patients  with  metastatic  disease 
(Kuniyasu et al., 1999; Slaton et al., 2001; Fukata et al., 2005; 
Campos et al., 2006; Pettaway et al., 2008). Finally, we show 
that treatment of tumor-bearing mice with an NO donor can 
elicit anti-metastatic effects by directly acting on the primary 
tumor.  These  findings  highlight  the  feasibility  of  using 
NO-inducing agents and combination immunotherapy to 
construct new strategies for therapy of metastatic disease.
RESULTS
IL-2/-CD40 induces NOS expression  
in tumor-associated macrophages
Previously, we showed that IL-2/-CD40 combination im-
munotherapy rebalances the profile of tumor-infiltrating   
leukocytes toward that of an anti-tumor Th1/M1-like pheno-
type (Weiss et al., 2009). Furthermore, we showed that IL-2/ 
-CD40 induced a significant reduction in arginase expres-
sion in tumor-associated macrophages. The balance between 
arginase  and  NO  expression  by  tumor-infiltrating  macro-
phages has been associated with the ability of these cells to 
promote or inhibit tumor development, respectively (Sica   
et al., 2008). We therefore analyzed NOS2 expression in pri-
mary tumors after IL-2/-CD40 therapy.
By Western blot analysis of tumor lysate samples, we 
found that IL-2/-CD40 increased NOS2 expression, as 
compared with control, IL-2, or -CD40 treatment (Fig. 1 A). 
By performing the experiment in IFN- knockout (GKO) 
mice, we confirmed that endogenous IFN- was required for 
the IL-2/-CD40–mediated induction of NOS2 in tumors 
(Fig. 1 A). Next, we determined the cellular source of NOS2 
expression in the tumor microenvironment, as both macro-
phages and granulocytes are potential sources that could be 
detected in tumors from IL-2/-CD40–treated mice. NOS2 
immunoreactivity was detected in cells that morphologically 
resembled macrophages only in tumors from IL-2/-CD40–
treated mice (Fig. 1 B). Using dual-color immunofluores-
cent microscopy, we found that a population of F4/80+ 
macrophages colocalized with intense immunoreactivity for 
NOS2 expression within the tumor microenvironment of 
toward a beneficial host immune response (Wigginton et al., 
1996a; Weiss et al., 2009). The IL-2/IL-12 immunotherapeu-
tic regimen has demonstrated objective benefits in some   
patients with melanoma and renal cell carcinoma (RCC; 
Gollob et al., 2003).
Nitric oxide (NO) is a critical mediator of macrophage 
function, and its expression is classically associated with the 
cytotoxic activity of macrophages against transformed cells 
(Nathan and Hibbs, 1991; Farias-Eisner et al., 1994). Further-
more, IL-12 treatment primes macrophages in vivo for en-
hanced NO production, and macrophage-associated NO   
may be an important component of successful IL-12–based 
immunotherapies (Wigginton et al., 1996b). Within the tumor   
microenvironment, NO can be generated by macrophages, 
neutrophils, endothelial cells, fibroblasts, and, in certain cases, 
by the tumor cells themselves. Despite its established role in 
anti-tumor responses, NO has been hypothesized to have a 
dual role because under certain circumstances, NO expression 
promotes tumor progression (Orucevic et al., 1999). The rea-
son for this apparent contradiction lies in the complex ability 
of NO to regulate diverse cellular processes, including cell ad-
hesion, invasiveness and proliferation, matrix remodeling, and 
angiogenesis (for review see Williams and Djamgoz, 2005). 
Furthermore, NO synthase (NOS) 2 expression has been 
shown to contribute to some of the critical immunosuppres-
sive properties of myeloid-derived suppressor cells (MDSCs) 
that  are  frequently  associated  with  tumors  (Serafini  et  al., 
2006a), and NO inhibition can result in augmented anti-tumor 
responses through the reversal of MDSC-mediated suppres-
sion (Serafini et al., 2006b). The local concentration of NO 
may partially explain its biphasic nature in cancer. On the one 
hand, high steady-state concentrations of NO result in P53 
phosphorylation, which is itself associated with tumor cell 
apoptosis, cell cycle delay, and DNA repair (Ambs et al., 1998; 
Thomas et al., 2004). High NO concentrations also impair 
the activity of matrix metalloproteinases (MMPs), which play 
important roles in matrix remodeling and the metastatic pro-
cess  (Liotta  and  Stetler-Stevenson,  1990;  Ridnour  et  al., 
2007). On the other hand, low concentrations of NO have 
been shown to promote the HIF-1 and/or MAPK-mediated 
promotion of tumor growth (Thomas et al., 2004) and low 
NO concentrations actually enhance MMP activity by inhib-
iting their endogenous inhibitor, tissue inhibitor of metallo-
proteinase (TIMP) 1 (Ridnour et al., 2007). Collectively, 
the levels of NO achieved within the tumor microenviron-
ment likely play a critical role in regulating the balance be-
tween tumor promoting and inhibiting properties of tumor- 
associated macrophages.
Previously, we showed that the IL-12–based immuno-
therapy IL-2/-CD40 elicits synergistic anti-tumor responses 
that are dependent on IL-12 (Murphy et al., 2003; Weiss et al., 
2009). We hypothesize that this is, in part, dependent on the 
priming of macrophages to produce high levels of NO that 
help establish a polarized tumor microenvironment whereby 
the macrophages display a classical M1 phenotype, character-
ized not only by high levels of NO production but also by JEM VOL. 207, October 25, 2010 
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therapy  to  reduce  primary  tumor 
burden (Fig. 2 A); however, it com-
pletely abrogated the ability of this 
combination immunotherapy to reduce the number of lung 
metastases (Fig. 2 B). Interestingly, for saline control-treated 
mice,  L-NAME  treatment  modestly,  yet  significantly,  re-
duced primary tumor burden by itself (Fig. 2 A). Addition-
ally, macrophage depletion similarly had no effect on the 
ability of IL-2/-CD40 to reduce the size of kidney tumors 
(Fig. 2 C) but macrophage depletion completely reversed   
the reduction in the number of lung metastases (Fig. 2 D).   
To further address the role for NOS2 in tumor progression, 
we next evaluated primary tumors and lung metastases in 
WT and NOS2/ mice. Although primary tumors in control-
treated WT and NOS2/ mice were indistinguishable, the 
treatment of NOS2/ mice with IL-2/-CD40 resulted in 
a significantly greater reduction in primary tumor burden,   
as  compared  with  WT  mice  (Fig.  2  E).  However,  the   
IL-2/-CD40–mediated reduction in lung metastases was 
significantly reversed in NOS2/ mice (Fig. 2 F). Collec-
tively, these data suggest that the immunotherapy-induced 
NO expression via tumor-associated macrophages is critical 
for the control of lung metastases but not the size of primary 
tumors in the kidney.
NO does not alter the ability of tumors to seed  
the lung and liver
To determine whether the inhibition of NO was somehow al-
tering the ability of Renca tumor cells to seed different organs, 
we inoculated mice with tumor cells via intravenous or intra-
splenic routes of injection to seed the lungs and liver, respec-
tively. For each route of tumor injection, an equivalent number 
of tumor nodules were observed in control (no L-NAME) or 
L-NAME–treated mice (Fig. 3, A and B). This suggests that 
IL-2/-CD40–treated mice (Fig. 1 B). It is noteworthy, how-
ever, that not all NOS2+ cells costained with F4/80. Although 
we believe it most likely that this population of cells represents a 
phagocytic cell that has down-regulated F4/80 expression, as 
has been reported for activated macrophages exposed to cyto-
kines from lymphoid-rich regions (Ezekowitz and Gordon, 
1982), we do not rule out the possibility that the degree of 
colocalization between F4/80 and NOS2 may also be attrib-
uted to the membrane association of F4/80 and cytoplasmic 
localization of NOS2. Although F4/80+ macrophages were 
evident in the tumors from -CD40–treated mice, these were 
NOS2 negative. No F4/80 immunoreactivity was detectable 
in tumors from vehicle control (VC; not depicted) or IL-2 
(Fig. 1 B)–treated mice. Gr1+ granulocytes were also present 
in tumors from IL-2/-CD40–treated mice (these appear as 
much smaller orange-stained cells in the two-color overlay); 
however, these were primarily localized in NOS2-negative 
areas (Fig. 1 C). Furthermore, the treatment of mice with the 
macrophage-depleting agent clodronate abrogated NOS2 ex-
pression, whereas Gr1-depletion had no effect (Fig. 1, B and C). 
These data confirm that IL-2/-CD40 induces significant 
NOS2 expression through a process that is dependent on tumor- 
associated macrophages.
Macrophage-dependent NOS expression is required  
for controlling lung metastases
To confirm the relative importance of macrophage-associated 
NO expression to tumor progression, we treated tumor-
bearing mice with the NOS inhibitor N-nitro-l-arginine 
methyl ester (L-NAME) for the duration of therapy. Treatment 
with L-NAME had no effect on the ability of IL-2/-CD40 
Figure 1.  IL-2/-CD40 induces NOS 
expression via tumor-associated macro-
phages. (A) WT and GKO mice were treated 
between days 11 and 21 as indicated in the 
Materials and methods. On day 22, mice 
were euthanized, and the primary tumor 
was dissected and homogenized in RIPA 
lysis buffer. The expression of NOS2 was 
determined by Western blot analysis.  
Hypoxanthine phosphoribosyltransferase 
(HPRT) was used as a loading control.  
(B and C) Tumors from treated WT mice were 
dissected on day 22, fixed in formalin, and 
analyzed by two-color immunofluorescent 
microscopy (200× magnification). NOS2 
immunoreactivity was visualized using 
Alexa Fluor 488 (green). (B and C) F4/80  
(B) and GR1 (C) immunoreactivity was visu-
alized using Alexa Fluor 594 (red). In some 
regions, colocalization of the two colors 
results in yellow staining. The results are 
representative of three separate experi-
ments. Bars, 100 µm.2458 Immunotherapy-induced NO controls lung metastasis | Weiss et al.
stimulation has no significant impact upon the ability for 
tumor cells to seed distant organs. Rather, they suggest that 
NO is an important regulator of the preceding ability of   
tumor cells to break away from the orthotopically growing 
primary kidney tumor, thereby allowing them to gain en-
trance into the vasculature and ultimately metastasize to dis-
tal organs.
IL-2/-CD40 reduces MMP2 and MMP9 expression  
and increases TIMP-1 and E-cadherin expression within  
the tumor microenvironment
Our results suggested that the NO-mediated inhibition of 
metastases was likely occurring proximal to the primary   
tumor  site.  Knowing  that  the  expression  and  activity  of 
MMPs  are  important  mediators  of  the  metastatic  process   
(Liotta and Stetler-Stevenson, 1990), we analyzed MMP2, 
MMP9, and TIMP-1 expression within the tumor micro-
environment after therapy. As shown in Fig. 4, IL-2/-CD40 
treatment, but not IL-2 or -CD40 alone, reduced the   
expression  of  both  MMP2  and  MMP9  within  tumors.   
NOS2 inhibition does not simply act by impairing the ability 
of Renca to seed and grow in the lung or liver. To further 
evaluate the role NO might play in regulating distant organ 
seeding, we treated mice bearing intravenously injected Renca 
tumor cells with the NO donor drug JS-K. We selected this 
NO donor because it has proven effective in several xenograft 
models (Kiziltepe et al., 2007; Maciag et al., 2009), because it 
releases NO specifically upon activation by glutathione, and 
this reaction is accelerated by glutathione S-transferase (GST; 
Shami et al., 2003), and because RCCs express GST (Simic et al., 
2009), which should allow for drug targeting to the tumor   
microenvironment (Shami et al., 2003). Treatment of mice 
bearing intravenously delivered Renca with either JS-K or the 
non–NO-releasing analogue JS-43-126 had indistinguishable 
effects on the number of tumor nodules in the lungs (Fig. 3 C). 
Collectively, these results indicate that NO blockade or 
Figure 3.  NO inhibition or stimulation does not impair the ability 
of tumors to seed the lung and liver. (A and B) WT mice were inocu-
lated intravenously (A) or intrasplenically (B) with Renca tumor. One-half 
of the mice were treated with L-NAME for the duration of the experiment. 
(A–C) WT mice were inoculated intravenously with Renca tumor and 
treated with either JS-43-126 or JS-K on days 1, 3, 6, 8, 10, and 13 after 
tumor injection. On day 14, mice were euthanized and the lungs (A and C) 
and livers (B) were collected and fixed in Bouin’s solution. The number of 
tumor nodules in each organ was determined by counting under a dis-
secting microscope. Each data point represents the results from an indi-
vidual mouse and each treatment group contained at least eight mice. 
The horizontal bars indicate the means for each treatment group.  
The data are derived from one experiment. The results in A and B are  
representative of two separate experiments. NS = not significant.
Figure 2.  Macrophage-dependent NOS expression is required for 
controlling lung metastases. WT and NOS2/ mice were treated as 
indicated. (A and B) Black bars indicate mice that were treated with L-NAME  
for the duration of the experiment. (C and D) For clodronate studies,  
mice received either saline control liposomes (white bars) or macrophage-
depleting clodronate (black bars) as detailed in the Materials and methods. 
(E and F) Black bars indicate results using NOS2/ mice. (A, C, and E) On 
day 22, mice were euthanized and the primary tumor was dissected and 
measured. Lungs from these treated mice were collected on the same day 
and fixed in Bouin’s solution. (B, D, and F) The number of lung metastases 
was counted under a dissecting microscope. In A–D, the pooled results 
from two experiments are shown and in E and F, the results from one ex-
periment are shown. The error bars indicate the standard error of the 
means for each treatment group. Each experiment consisted of 10 mice/
treatment group. *, P < 0.05; **, P < 0.005 for the indicated comparisons.JEM VOL. 207, October 25, 2010 
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Figure 4.  IL-2/-CD40 reduces MMP2 and MMP9 expression and increases TIMP-1 and E-cadherin expression within the tumor microenvi-
ronment. (A) WT and GKO mice were treated as indicated. (B) WT mice were treated as indicated with or without continuous L-NAME treatment. On day 22,  
mice were euthanized and the primary tumor was dissected and homogenized in RIPA lysis buffer. The expression of MMP2, MMP9, TIMP-1, and  
E-cadherin was determined by Western blot analysis. HPRT was used as a loading control. The results are representative of at least three separate experi-
ments. (C) For each protein, the corresponding band intensity was determined by densitometric analysis. The results were then divided by the band inten-
sity for the corresponding HPRT loading control. For MMP9, the intensity of both major bands was analyzed together. The graphs represent the mean and 
standard errors for the quantitated results obtained from all experiments. *, P < 0.05; **, P < 0.005. The black bars indicate WT mice, the white bars indi-
cate GKO mice, and the hatched bars indicate L-NAME–treated WT mice. (D) The expression of phosphorylated P53 (Ser 15) and total P53 levels was ana-
lyzed in treated samples by Western blot analysis. The graph illustrates the band intensity ratio of phosphorylated P53 relative to the corresponding total 
P53 levels from one experiment. The black and hatched bars indicate WT mice treated in the absence or presence of L-NAME, respectively.2460 Immunotherapy-induced NO controls lung metastasis | Weiss et al.
Importantly, the expression of both the inactive form (72 kD) 
and active form (63 kD) of MMP2 was reduced as compared 
with control-treated mice. The reduction in MMP2 and 
MMP9 expression was not observed in GKO mice (Fig. 4 A) 
or in mice treated with L-NAME (Fig. 4 B), although 
basal levels of both molecules were significantly lower in   
L-NAME–treated mice (Fig. 4 C). These findings implicate 
IFN-–mediated NO expression in the control of MMP ex-
pression within tumors. Furthermore, IL-2/-CD40 treat-
ment induced a significant increase in TIMP-1 expression 
within tumors that was independent of both IFN- (Fig. 4 A) 
and NOS2 expression (Fig. 4 B). This latter finding is con-
sistent with the ability of NO to regulate TIMP-1 expres-
sion at low concentrations but not higher concentrations 
(Ridnour et al., 2007). IL-2/-CD40 also induced an IFN-– 
dependent increase in E-cadherin expression (Fig. 4, A and C).   
Although IL-2/-CD40 mediated a detectable increase in 
E-cadherin expression in L-NAME–treated mice (Fig. 4 B), 
this did not reach statistical significance as compared with 
L-NAME–treated control mice, the latter of which exhib-
ited significantly lower levels of E-cadherin expression, as 
compared with non–L-NAME–treated mice (Fig. 4 C).   
Finally, IL-2/-CD40 treatment induced P53 phosphoryla-
tion, a marker of NO-mediated signaling suggestive of ele-
vated steady-state NO levels which was not observed in the 
presence of L-NAME (Fig. 4 D). Collectively, these data 
demonstrate that the high level of NO achieved within   
the tumor microenvironment by IL-2/-CD40 treatment 
correlates with a potentially reduced metastatic potential   
of tumor cells through the reduction in local MMP ex-
pression and increased expression of molecules involved in 
the regulation of MMP activity (TIMP-1) and cell adhe-
sion (E-cadherin).
IL-2/-CD40 reduces MMP9 activity within  
the tumor microenvironment
TIMP-1 is a well established endogenous inhibitor of MMP 
activity, and active MMP2 has also been shown to cleave 
pro-MMP9 into the active form (Liotta and Stetler-Stevenson, 
1990). Furthermore, NO regulates both TIMP-1 and MMP9 
(Ridnour et al., 2007). We therefore determined whether 
MMP enzymatic activity was reduced in response to IL-2/ 
-CD40  treatment.  By  gel  zymography,  IL-2/-CD40 
treatment  of  tumor-bearing  mice  significantly  reduced 
MMP9 activity within the tumor microenvironment (Fig. 5). 
Consistent  with  the  previous  data,  the  IL-2/-CD40– 
mediated inhibition of MMP9 activity was not observed in 
GKO mice and was markedly reduced in mice treated with 
L-NAME. The partial ability of L-NAME to inhibit MMP9 
activity was not surprising because MMP9 can also be in-
hibited by IFN- (Duluc et al., 2009). These data collec-
tively demonstrate the ability of IL-2/-CD40 combination 
treatment to induce the IFN-– and NO-dependent reduc-
tion in MMP9 expression and activity within the tumor   
microenvironment that may, in turn, impair metastatic spread 
to the lungs.
Treatment with an NO donor, both as a single agent or in 
combination with IL-2/-CD40, reduces MMP-2 and MMP-9, 
but not TIMP-1 or E-cadherin, expression within tumors
To further confirm the role for NO in regulating MMP-2/-9, 
TIMP-1, and E-cadherin expression in primary tumors, we 
evaluated the expression of these molecules after treatment of 
mice with JS-K or JS-43-126 alone or in combination with 
IL-2 and/or -CD40. By Western blot analyses, we found 
that treatment with JS-K, alone or in combination with IL-2 
or -CD40, significantly reduced the levels of both inactive 
and active forms of MMP-2, as well as MMP-9, as compared 
with the corresponding mice treated with JS-43-126 (Fig. 6, 
A and B). Interestingly, when JS-K was used in combination 
with IL-2 + -CD40, MMP-2 levels, and especially MMP-9 
levels, were significantly reduced even further, as compared 
with all other treatment groups. In contrast, treatment with 
JS-K had no effect on TIMP-1 levels within primary tumors. 
The basal or IL-2/-CD40–induced expression of E-cadherin 
was also unaffected by JS-K treatment, although it is interest-
ing to note that E-cadherin levels were significantly reduced 
in tumors from IL-2 + JS-K– and -CD40 + JS-K–treated 
mice (Fig. 6 B). Overall, these findings indicate that the NO 
donor JS-K is capable of significantly down-modulating 
MMP-2 and MMP-9, but not TIMP-1 or E-cadherin, expres-
sion within tumors. Our data further suggest that NO levels 
achieved within the tumors can be more effectively targeted 
using combination therapies for the collaborative reduction of 
tumor-associated MMP-2 and MMP-9 expression.
Figure 5.  IL-2/-CD40 induces the IFN-– and NO-dependent 
reduction in MMP9 activity within the tumor microenvironment.  
(A) WT and GKO mice were treated as indicated. (B) WT mice were treated 
as indicated with or without continuous L-NAME treatment. On day 22, 
mice were euthanized and the primary tumor was dissected and homog-
enized in RIPA lysis buffer. MMP9 activity was determined by gel zymog-
raphy. Note that because the amount of lysate loaded in each lane was 
based on the same total protein concentration used for Western blot 
analyses in the previous figure, the same corresponding HPRT Western 
blot that was used as a loading control in the previous figure is shown for 
referencing purposes as a gel loading control. The results are representa-
tive of three separate experiments.JEM VOL. 207, October 25, 2010 
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metastatic disease. Because curative responses after combina-
tion therapy using IL-2/-CD40 (as well as IL-2/IL-12) re-
quire the surgical removal of primary tumors (Wigginton et al., 
1996a; Murphy et al., 2003; Weiss et al., 2009), we adapted our 
tumor model to contrast the treatment with JS-K either be-
fore or after the surgical removal of the tumor-bearing kidney 
on day 11. Mice received JS-K either on days 4, 6, 8, and 10 
(JSK early) or on days 13, 15, 18, 20, and 22 (JSK late). Saline 
control (VC) or IL-2/-CD40 treatment always commenced 
on day 12 and went for two weekly cycles. As compared with 
the survival results obtained using IL-2/-CD40 in the ab-
sence of any JS-K treatment, the inclusion of JS-K treatment 
before nephrectomy slightly enhanced mouse survival, al-
though differences were not statistically significant (Fig. 7 C). 
Treatment with an NO donor reduces lung metastases  
and improves survival
Our data indicated that endogenous NO expression was a 
critical component of the immunotherapy-mediated control 
of lung metastases but not primary tumor burden. To further 
confirm this, we treated tumor-bearing mice with JS-K or 
JS-43-126 and evaluated primary tumors and lung metastases. 
Consistent  with  our  previous  results,  we  found  that  JS-K 
treatment had no effect on primary tumor weights (Fig. 7 A) 
but it significantly reduced the number of lung metastases 
(Fig. 7 B). When mice were treated with JS-K in combination 
with either IL-2 or -CD40, the anti-tumor effects were no 
better than single agent treatment (unpublished data). Finally, 
we evaluated long-term survival of JS-K–treated mice bearing 
Figure 6.  Treatment with the NO donor JS-K reduces MMP-2 and MMP-9 expression in primary tumors. WT mice were treated with 
saline (VC), IL-2, and/or -CD40 in combination with either the NO donor JS-K or the non–NO-releasing analogue JS-43-126. On day 22, mice 
were euthanized and the primary tumor was dissected and homogenized in RIPA lysis buffer. (A) The expression of MMP2, MMP9, TIMP-1, and  
E-cadherin was determined by Western blot analysis. HPRT was used as a loading control. The results are representative of three separate ex-
periments. (B) For each protein, the corresponding band intensity was determined by densitometric analysis. The results were then divided by the 
band intensity for the corresponding HPRT loading control. Graphs represent the mean and standard errors for the quantitated results obtained 
from all three experiments. *, P < 0.05; **, P < 0.005. The black bars indicate JS-43-126 control-treated mice and the white bars indicate JS-K–
treated mice.2462 Immunotherapy-induced NO controls lung metastasis | Weiss et al.
DISCUSSION
Previously, we showed that the IL-2/-CD40 immunothera-
peutic regimen results in synergistic anti-tumor responses 
(Murphy et al., 2003; Weiss et al., 2009). IL-2/-CD40, but 
not treatment with either IL-2 or -CD40 alone, significantly 
reduced primary tumor size and the number of lung metasta-
ses and resulted in improved long-term survival. We now 
demonstrate  that  the  induction  of  macrophage-dependent 
NO expression within the tumor microenvironment is a criti-
cal component of this successful therapy. This finding builds 
upon our previous studies showing that tumors from IL-2/ 
-CD40–treated mice contain significant infiltration by IFN-– 
producing CD8+ T cells (Weiss et al., 2009), which are also 
required for the control of metastases because their depletion, 
even after nephrectomy of primary tumors, impaired survival 
(Murphy et al., 2003). It is therefore logical to propose a sce-
nario whereby these activated effector cells within the tumor 
microenvironment contribute to the IFN-–dependent up-
regulation of NOS2 expression via macrophages that we now 
demonstrate are critical for the control of metastatic spread. 
Interestingly, the ability of IL-2/-CD40 to control primary 
tumors was independent of NO, whereas the reduction in 
lung metastases was absolutely dependent on NO. Indeed, the 
identical reversal of IL-2/-CD40–mediated anti-metastatic 
effects achieved by NOS2 inhibition and macrophage de-
pletion, as well as in NOS2/ mice, strongly supports the 
conclusion  that  IL-2/-CD40  induces  the  recruitment  of 
macrophages into the tumor microenvironment where NO 
production is critical for the control of metastatic spread. Pre-
sumably, the reduction in primary tumor burden is dependent 
on other components achieved by this combination therapy, 
such as the tumor infiltration by effector CD8+ T cells that   
facilitate adaptive immune responses and generate protection 
from tumor rechallenge (Murphy et al., 2003; Weiss et al., 
2009). With respect to the primary kidney tumor, it is im-
portant to note that a significant reduction was observed in   
L-NAME–treated  mice  but  not  NOS2/  or  clodronate-
treated WT mice. Moreover, IL-2/-CD40 reduced primary 
tumors to a much greater degree in NOS2/ mice. Collec-
tively, these data suggest that although NOS2 is central to the 
control of lung metastases, other NOS isoforms, perhaps de-
rived from tumor-associated vasculature, appear to be more 
central to the control of primary tumor growth. Because 
RCC is characterized by a high frequency of metastasis and 
poor prognosis (Holland, 1973), an improved understanding 
of the mechanisms whereby this separable process may be po-
tentially controlled is of considerable importance.
Several elegant studies have implicated macrophages in 
the promotion of metastatic potential (Lin et al., 2001; Qian 
et al., 2009). In these studies, the expression of macrophage-
derived CSF-1 was directly implicated in regulating breast 
cancer metastasis rather than the growth of primary tumors 
(Lin et al., 2001). Thus, elevated CSF-1 levels frequently ob-
served in solid tumor patients are explicitly linked with the 
degree of macrophage infiltration into primary tumors and 
poor  prognosis.  Moreover,  macrophage  depletion  blocked 
It is noteworthy, however, that no enhancement in survival 
was  observed  when  mice  were  treated  with  JS-K  after   
nephrectomy  of  the  tumor-bearing  kidney. Treatment  of 
mice with JS-K in the absence of IL-2/-CD40 also failed   
to improve survival, regardless of when JS-K treatment was 
initiated. These findings suggest that although JS-K as a   
single agent appears ineffective, the IL-2/-CD40 therapy   
previously shown to significantly promote survival might 
modestly be enhanced by JS-K treatment. The requirement 
for JS-K administration before nephrectomy would be con-
sistent with the conclusion that the NO donor needs to act 
directly within the primary tumor microenvironment to exert 
its anti-metastatic effects.
Figure 7.  Treatment with the NO donor JS-K reduces lung  
metastases and improves survival by acting directly on the pri-
mary tumor. (A and B) WT mice were treated with either the NO donor 
JS-K or the non–NO-releasing analogue JS-43-126. (A) On day 22, mice 
were euthanized and the primary tumor was dissected and measured. 
(B) Lungs from these treated mice were collected on the same day and 
fixed in Bouin’s solution. The number of lung metastases was counted 
under a dissecting microscope. The pooled results from two experi-
ments each consisting of 10 mice/treatment group are shown.  
*, P < 0.05; **, P < 0.002 for the indicated comparisons. The error bars 
indicate the standard error of the means for each treatment group.  
(C) For studies of tumor progression, some mice were treated with JS-K 
only on days 4, 6, 8, and 10 (JSK early). All mice received surgical re-
moval of the tumor-bearing kidney on day 11 followed treatment with 
IL-2/-CD40 or saline (VC) beginning on day 12 for 2 wk. Some mice 
were treated with JS-K on days 13, 15, 18, 20, and 22 (JSK late). Sur-
vival analysis was plotted according to the Kaplan-Meier method. The 
results are from one experiment in which each treatment group con-
tained at least eight mice.JEM VOL. 207, October 25, 2010 
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activity at the protein level because the MMP-independent 
functions of TIMP-1 are anti-apoptotic, which would other-
wise protect the tumor (Liotta and Stetler-Stevenson, 1990). 
It is noteworthy that several studies have correlated increased 
MMP expression in tumor samples with metastatic potential 
in murine studies (Miyake et al., 1999), as well as tumor pro-
gression and poor prognosis in RCC patients (Harada et al., 
2006; Kawata et al., 2007). Thus, an important immunother-
apeutic goal should be the redirection of immune responses 
such that MMP levels are reduced.
Conflicting results have been reported for NO in cancer 
progression studies. In certain studies, NOS expression has 
been positively correlated with tumor invasiveness (Orucevic 
et al., 1999). Moreover, NO inhibition augmented anti- 
tumor immunity by interfering with NOS2 activity that is 
critical for MDSC suppressor function (Serafini et al., 2006b). 
However, other studies have demonstrated an inverse corre-
lation between cancer progression and NOS expression (for 
review see Williams and Djamgoz, 2005). Furthermore, NO 
has been shown to both positively and negatively regulate 
apoptosis, cell invasion, and angiogenesis (Ambs et al., 1998; 
for review see Williams and Djamgoz, 2005). The dual na-
ture of NO arises from its concentration-dependent ability to 
regulate numerous cellular processes that may impact meta-
static potential. In tumors, different concentration thresholds 
of NO appear to elicit a discrete set of signal transduction 
pathways (Thomas et al., 2004). Low concentrations of NO 
promoted the growth, invasion, and metastasis of murine 
mammary tumors (Jadeski et al., 2000). Recently, it has also 
been shown that low levels of NO result in a transient in-
crease in ERK phosphorylation and a signaling cascade re-
sulting in increased angiogenesis, cell migration, adhesion, 
and proliferation that may be consistent with the promotion 
of tumor growth (Thomas et al., 2004). In contrast, high NO 
levels have been shown to suppress tumor growth and metas-
tasis (Dhar et al., 2003; Le et al., 2005). Consistently, the high 
levels of NO-induced P53 phosphorylation and events asso-
ciated with reduced angiogenesis, cell migration, adhesion, 
and proliferation each correlate with reduced tumor progres-
sion (Ambs et al., 1998; Thomas et al., 2004). Our data are 
consistent with this biphasic model which has been proposed 
for NO (Ridnour et al., 2006). Under basal control-treated 
conditions, where low levels of NO are expected, we ob-
served a significant reduction in tumor growth after treating 
mice with an inhibitor of NO alone. In the context of a 
strong immunotherapeutic regimen such as IL-2/-CD40, 
we observed significant increases in NOS expression as well 
as increased phosphorylation of P53 within tumor lysates, 
which serves as an important indicator that high levels of NO 
have been achieved. Importantly, our results suggest that the 
high levels of NO achieved within the tumor microenviron-
ment after IL-2/-CD40 treatment are critical for the suppres-
sion of tumor metastasis. We demonstrate that this is closely 
associated with the IFN-– and NO-dependent modulation 
of MMP2, MMP9, and TIMP-1 expression and activity 
(Ridnour et al., 2007).
seeding and metastatic growth of tumor cells in the lungs 
(Qian et al., 2009). However, we believe that some variables 
may complicate ascribing the role for macrophages in the pro-
gression of some tumors. For example, although mice bearing 
CSF-1–rich tumors in the breast have a dramatic degree of 
macrophage infiltration, our previous (Weiss et al., 2009) and 
current (Fig. 1 B) findings indicate that these cells do not rep-
resent a major component of the mononuclear cell infiltrate of 
orthotopic Renca tumors under basal conditions. It remains 
unclear whether this is a result of tumor- or possibly organ-
specific differences between these experimental models. This 
distinction may, at least in part, explain why macrophage de-
pletion, in the absence of immunotherapy, did not signifi-
cantly alter the number of lung metastases in our studies.
Although macrophages may frequently be associated with 
poor outcome, their remarkable heterogeneity and plasticity 
underscores their promise as cellular targets for improved 
therapeutic outcome. Our data are consistent with the con-
clusion that IL-2/-CD40, and likely other IL-12–based im-
munotherapeutic regimens, alters macrophage populations   
to help induce the establishment of a desirable Th1/M1-like   
tumor microenvironment. IL-2/-CD40 induces significant 
levels of IL-12 and IFN- expression, both of which are 
markers of M1 polarized macrophages. Moreover, within the 
tumor itself, IL-2/-CD40 induces significant infiltration by 
NK cells, CD8+ T cells, and macrophages (Weiss et al., 2009). 
Thus, rather than tumor promotion, in the IL-2/-CD40 
immunotherapeutic setting, these tumor-associated macro-
phages display an anti-tumor M1 phenotype, with reduced 
arginase expression (Weiss et al., 2009) and increased NOS 
expression. This finding is consistent with a recently pro-
posed model whereby macrophages retain a large degree 
of plasticity, allowing their effector functions to be repro-
grammed by components of their microenvironment. Impor-
tantly, IL-12 has emerged as a critical regulator of this process 
(Watkins et al., 2007). Moreover, our data demonstrate   
IL-2/-CD40–mediated reduced MMP9 expression, which 
is also consistent with the M1 polarization of macrophages 
because elevated MMP9 levels have been more closely asso-
ciated with alternatively activated M2 macrophages (Lolmede 
et al., 2009). Thus, the observed modulation of MMP9 and 
TIMP-1 expression within tumors may be a reflection of 
Th1-polarized macrophages as well as the reduced frequency 
of MDSC in tumors from IL-2/-CD40–treated mice (Weiss 
et al., 2009). Although the reduced enzymatic activity of 
MMP9 within tumors might simply be a result of lower 
MMP9 expression, we also find it noteworthy that the levels 
of MMP9 activity did not always follow the same trend as 
that observed for MMP9 expression levels. For example, al-
though L-NAME by itself significantly reduced MMP9 ex-
pression, the activity of MMP9 under these same conditions 
was enhanced, a finding which is consistent with our previ-
ous study showing enhanced MMP9 activity after NO inhi-
bition and the biphasic nature of MMP regulation by NO 
(Ridnour et al., 2007). It is also likely that the elevated 
TIMP-1 levels we observed are functioning to inhibit MMP9 2464 Immunotherapy-induced NO controls lung metastasis | Weiss et al.
expression within the tumor microenvironment to regulate the 
expression and activity of MMP and E-cadherin and relate this 
to the metastatic potential of a progressing tumor. Specifically, 
we noted that IL-2/-CD40–induced NO expression increases 
E-cadherin and reduces MMP expression specifically within 
the primary tumor microenvironment. E-cadherin is an adhe-
sion molecule that is involved in cell–cell adhesion and respon-
sible for maintenance of epithelial tissue. The loss of E-cadherin 
expression has been associated with an increased risk for metas-
tasis in human tumors (Oka et al., 1993). Moreover, the treatment 
of mice with an NO donor also significantly reduced MMP-2 
and MMP-9 expression within tumors. After cell detachment 
from the primary tumor, their invasion of the host stroma is a 
prerequisite for metastasis (Liotta and Stetler-Stevenson, 1990). 
In this regard, the levels and activity of MMP2 and MMP9   
directly correlate with the invasion and metastatic potential of 
tumor cells. Many studies have used multivariate analysis to 
demonstrate that the MMP/E-cadherin ratio is an independent 
prognostic indicator of overall patient survival for many solid 
tumors, including RCC (Kuniyasu et al., 1999; Slaton et al., 
2001; Fukata et al., 2005; Campos et al., 2006; Pettaway et al., 
2008). Thus, IL-2/-CD40 immunotherapy should achieve a 
low MMP/E-cadherin ratio, the most favorable outcome, via 
both a reduction in MMP expression and activity and a con-
comitant increase in E cadherin expression in primary tumors. 
We believe that the relative levels of MMP and E-cadherin   
expression within the tumor microenvironment represent an 
important target and molecular readout for the successful   
immunotherapy of metastatic diseases.
Collectively, our data demonstrate the feasibility of using 
combination immunotherapy for the control of metastases. 
The localized expression of NO specifically within the tumor 
microenvironment serves as an important molecular readout, 
as this is critical for the regulation of MMP activity and adhe-
sion molecule expression that underlies the inhibition of the 
metastatic process. The tumor-targeted delivery of JS-K fur-
ther highlights the potential for context-dependent use of NO   
agonists in anti-tumor therapies.
MATERIALS AND METHODS
Mice. BALB/c WT mice were obtained from the Animal Production Area 
of the National Cancer Institute (NCI) at Frederick, MD. BALB/c GKO and 
NOS2/ mice were obtained from The Jackson Laboratory. PCR prim-
ers for genotyping GKO mice were 5-ATCGACAAGACCGGCTTC-
CATCCG-3 and 5-TCAGCGCAGGGGCGCCCGGTTCTTT-3. PCR 
primers  for  genotyping  NOS2  mice  were  5-ACATGCAGAATGAGT-
ACCGG-3, 5-TCAACATCTCCTGGTGGAAC-3, and 5-AATATGC-
GAAGTGGACCTCG-3. Mice (8–10 wk of age) were used in accordance 
with an approved protocol by the NCI-Frederick Institutional Animal Care 
and Use Committee.
Cells and reagents. The renal adenocarcinoma of BALB/c origin (Renca) 
was passaged intraperitoneally as previously described (Williams et al., 1981). 
Recombinant human IL-2 (Teceleukin) was obtained from the NCI. Ago-
nist rat anti–mouse CD40 (clone FGK115B3) was purified from ascites as 
previously described (Murphy et al., 2003; Weiss et al., 2009). Endotoxin 
was <1 EU/mg of antibody, as determined by chromogenic Limulus Ame-
bocyte Lysate kit (QCL-1000; Cambrex). Purified rat IgG was purchased 
from Jackson ImmunoResearch Laboratories. L-NAME was purchased from 
NO-releasing prodrugs have been used to treat coronary 
disease; however, their systemic administration may result in 
dose-limiting vasodilation and hypotension. As a result of the 
relevant role that NO plays in modulating angiogenesis,   
tumor cell growth, and sensitization to apoptosis, these agents 
have also shown considerable promise for tumor immuno-
therapy (Bonavida et al., 2008). Two NO-releasing vasodi-
lating drugs, isosorbide mononitrate (ISMN) and isosorbide 
dinitrate (ISDN), inhibited tumor growth and metastasis in 
the Lewis lung carcinoma model in mice, in association with 
an inhibition of angiogenesis (Pipili-Synetos et al., 1995). 
However, the NO donor that we successfully used, JS-K, 
does have a major advantage over other NO-inducing drugs 
that warrants further consideration for its use in anti-tumor 
studies. JS-K was specifically designed to overcome the un-
desirable vasodilation and hypotension side effects (Shami et al., 
2003). JS-K mediates the relatively slow release of NO in 
microenvironments rich in glutathione, such as many tumor 
microenvironments including RCC (Simic et al., 2009). JS-K 
was shown to inhibit breast cancer invasion in vitro (Simeone 
et al., 2008). We now show for the first time that JS-K sig-
nificantly inhibited lung metastasis in vivo. This finding, col-
lectively with our observation that NOS2 inhibition reversed 
lung metastasis but had no effect on the growth of primary 
tumors, indicates that the two anti-tumor effects (primary 
and  metastatic)  of  the  IL-2/-CD40  immunotherapy  are 
separable and supports strongly the role for macrophage- 
dependent NO expression in the control of metastatic spread   
to the lungs. Interestingly, the anti-metastatic benefits of JS-K 
treatment required an intact tumor because these effects were 
abolished when the tumor-bearing kidney was resected. Fur-
thermore, the early administration of JS-K, followed by   
IL-2/-CD40 therapy, resulted in slightly enhanced survival, 
as compared with IL-2/-CD40 alone, which would further 
be consistent with this model. We also found that the inhibi-
tion of NOS2 had no effect on the ability of Renca tumors 
to seed either the lungs or liver when administered via intra-
venous or intrasplenic routes, respectively. Collectively, these 
findings strongly suggest that NO prevents metastatic spread 
by acting directly at the primary tumor site. Indeed, our data 
suggest that NO donors will likely not provide clinical bene-
fit in patients that have their primary tumors surgically re-
moved. The clinical use of NO donors such as JS-K may thus 
be more appropriate in cases where surgical removal of pri-
mary tumors is not possible or, potentially, in combination 
with other therapies for the control of tumor recurrence. 
Conversely, it could be interesting to consider the possibility 
that some patients regularly taking iNOS inhibitors for other 
conditions (e.g., erectile dysfunction) might show slower pri-
mary tumor growth but an enhanced propensity for meta-
static dissemination.
Within the primary tumor, we demonstrate several critical 
molecular changes in response to IL-2/-CD40–induced NO 
expression  that  may  inhibit  the  metastatic  process.  To  our 
knowledge, our study is the first to demonstrate, in an in vivo 
model of metastatic disease, the ability for high levels of NO JEM VOL. 207, October 25, 2010 
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Statistical  analysis. Statistical differences were analyzed using a Mann-
Whitney U test (Prism; GraphPad Software, Inc.). Significance was indicated 
by P < 0.05 values.
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